Monkeypox Vaccine Approval A Shot In The Arm For Bavarian
Executive Summary
Nigeria's monkeypox outbreak represents opportunity for Danish company still looking to overcome cancer vaccine setback.
You may also be interested in...
Vaccines Boost Priority Profile Of US FDA’s Biologic Center 2019 Approvals
Tropical diseases were not neglected by the Center for Biologics Evaluation and Research in 2019, producing three novel vaccines (which earned three priority review vouchers) and tilting the approval class toward expedited review programs.
Keeping Track: Intercept Submits OCA For NASH; Zogenix’ Fintepla Returns; US FDA Approves Bavarian Nordic Vaccine
The latest drug development news and highlights from our US FDA Performance Tracker
AstraZeneca Buys Priority Review Voucher With Two Big Filings On The Horizon
AstraZeneca paid $95m to Swedish Orphan Biovitrum for the voucher, which it could use to expedite the FDA review of roxadustat or trastuzumab deruxtecan.